3,222 Shares in Johnson & Johnson $JNJ Purchased by Connecticut Capital Management Group LLC

Connecticut Capital Management Group LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 3,222 shares of the company’s stock, valued at approximately $667,000.

A number of other hedge funds also recently bought and sold shares of the stock. Plancorp LLC raised its position in Johnson & Johnson by 0.3% in the 4th quarter. Plancorp LLC now owns 15,889 shares of the company’s stock valued at $3,288,000 after purchasing an additional 45 shares in the last quarter. Baron Silver Stevens Financial Advisors LLC raised its position in Johnson & Johnson by 0.8% in the 4th quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,645 shares of the company’s stock valued at $1,168,000 after purchasing an additional 45 shares in the last quarter. Strategic Financial Services Inc. raised its position in Johnson & Johnson by 0.5% in the 4th quarter. Strategic Financial Services Inc. now owns 8,995 shares of the company’s stock valued at $1,862,000 after purchasing an additional 45 shares in the last quarter. WealthCollab LLC raised its position in Johnson & Johnson by 4.7% in the 4th quarter. WealthCollab LLC now owns 1,015 shares of the company’s stock valued at $210,000 after purchasing an additional 46 shares in the last quarter. Finally, MMA Asset Management LLC increased its holdings in shares of Johnson & Johnson by 1.3% in the 4th quarter. MMA Asset Management LLC now owns 3,600 shares of the company’s stock valued at $745,000 after acquiring an additional 46 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced it will hold its second-quarter earnings conference call on July 15, reinforcing near-term focus on results, guidance, and management commentary. Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
• Positive Sentiment: DePuy Synthes, J&J’s orthopedic business, struck an exclusive distribution deal for the NOVOSIS bone graft product, adding another growth-oriented medtech move. DePuy Synthes secures exclusive NOVOSIS bone graft distribution partnership
• Positive Sentiment: Market commentary highlighted J&J as one of several large-cap pharma stocks worth holding as the industry recovery accelerates, supporting sentiment toward the stock. 4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
• Positive Sentiment: J&J was reported to have an average brokerage recommendation of “Moderate Buy,” suggesting analysts remain constructive on the shares. Johnson & Johnson Receives Average Recommendation of Moderate Buy from Brokerages
• Neutral Sentiment: J&J also presented at Bernstein’s Strategic Decisions Conference, but the transcript does not point to a fresh, stock-moving surprise by itself. Johnson & Johnson Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
• Negative Sentiment: Talc litigation remains an overhang, with new verdict headlines reinforcing legal risk that could pressure valuation multiples. Assessing Johnson & Johnson Valuation After Guidance Raise Growth Initiatives And Talc Litigation Update
• Negative Sentiment: Broader healthcare weakness also weighed on sentiment, with pharma and healthcare stocks described as a drag on the market in recent trading. Dow Gives Back Early Gains. Healthcare Stocks Are a Drag.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Citigroup increased their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Daiwa Securities Group increased their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. The Goldman Sachs Group increased their price objective on Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, April 15th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a research note on Wednesday, May 13th. Finally, Raymond James Financial raised their price target on Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $231.38 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a fifty day moving average price of $233.41 and a 200 day moving average price of $224.50. The company has a market cap of $556.97 billion, a PE ratio of 26.75, a P/E/G ratio of 2.25 and a beta of 0.27. Johnson & Johnson has a 1-year low of $149.04 and a 1-year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.